--- title: "CSL Ltd Earnings Call: Turnaround Gains vs. Headwinds" type: "News" locale: "en" url: "https://longbridge.com/en/news/297250341.md" description: "CSL Ltd reported a statutory net loss of $2.6 billion in FY '26, primarily driven by $7.1 billion in pretax impairments linked to Vifor and other assets. Despite this, the company generated robust operating cash flow of $3.5 billion, enabling share buybacks and maintaining dividends. Management highlighted early benefits from a transformation program, delivering $176 million in savings ahead of schedule. Key segments showed mixed results: Seqirus grew flu revenue despite overall decline due to non-recurring avian flu sales, while CSL Behring saw improving immunoglobulin trends. Vifor faces significant headwinds with expected revenue declines. FY '27 guidance anticipates modest underlying NPAT growth of ~5%." datetime: "2026-08-28T00:28:47.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/297250341.md) - [en](https://longbridge.com/en/news/297250341.md) - [zh-HK](https://longbridge.com/zh-HK/news/297250341.md) generator: "portal-rs" --- # CSL Ltd Earnings Call: Turnaround Gains vs. Headwinds Csl Ltd ((CSLLY)) has held its Q4 earnings call. Read on for the main highlights of the call. CSL Ltd’s latest earnings call painted a cautiously optimistic picture, with early benefits from a sweeping transformation program, strong cash generation, and solid product momentum set against hefty impairments and mounting structural challenges at Vifor and in China albumin. Management struck a tone of disciplined rebuilding, signaling confidence in a gradual return to profitable growth despite an FY ’26 statutory loss. ## Robust cash flow underpins buybacks and steady dividend Operating cash flow reached $3.5 billion, enabling CSL to complete an AUD 1.0 billion share buyback while launching a fresh AUD 1.1 billion authorization for FY ’27. The board held the full‑year dividend at $2.92 per share in U.S. dollars, and net debt to EBITDA ended at 1.8x, comfortably within the company’s target leverage band. ## Transformation savings running ahead of schedule CSL’s transformation program delivered $176 million of savings in FY ’26, well ahead of the $100 million target and already reshaping the cost base. Management expects about $220 million of additional savings in FY ’27, lifting annualized savings toward $400 million and potentially to $550 million in FY ’28, with part of the benefit reinvested into growth initiatives. ## Seqirus outgrows the flu market despite headline decline Seqirus was the only global vaccine player to grow seasonal influenza revenue, posting a 4% gain overall and 5% growth in both adjuvanted and cell‑based portfolios. Total Seqirus revenue fell 8% to $2.0 billion, however, as last year’s avian influenza sales did not repeat, masking underlying product and market share gains. ## Immunoglobulin momentum improves at CSL Behring CSL Behring revenue slipped 1% in constant currency to $11.4 billion, but immunoglobulin trends turned more encouraging through the year. While full‑year Ig sales were broadly flat, second‑half revenue rose 7% versus the prior comparable period and 4% sequentially, reflecting early payback from U.S. and China commercial investments and stable patient share in HIZENTRA. ## Newer therapies deliver promising growth The company highlighted strong traction from its newer portfolio, with ANDEMBRY’s launch running ahead of expectations and now spanning 19 markets. HEMGENIX revenue advanced 25% year on year, while CSL pushed its pipeline forward with a Phase III start for a VarmX candidate and selective out‑licensing such as clazakizumab to concentrate resources. ## Plasma network optimization targets productivity and yields CSL intensified its focus on plasma economics, closing underperforming collection centers without reducing total volumes and shifting some U.S. sites to the Haemonetics platform. Yield‑improvement projects are underway and construction has begun on the Kankakee IG facility, as the group experiments with digital donor engagement and AI tools to cut per‑unit supply costs. ## Cost discipline balanced with targeted investment Management emphasized tighter cost control, with R&D spending down 13% to $1.2 billion and general and administrative costs also falling 13% in FY ’26. Even so, CSL is continuing to fund strategic priorities, including roughly $50 million invested in VarmX programs and about $30 million funneled back into commercial initiatives to support future revenue growth. ## FY ’27 outlook: modest growth amid mixed segment trends For FY ’27, CSL guided to group revenue broadly in line with FY ’26 and underlying NPAT growth of about 5% at constant currency, with a modest FX headwind. Behring is expected to post mid‑single‑digit revenue growth driven by mid‑ to high‑single‑digit Ig expansion, Seqirus to grow at a low‑single‑digit pace, and Vifor to record a steep ~25% revenue decline. ## Heavy impairments drive statutory loss The headline statutory result was heavily distorted by $7.1 billion of pretax impairments in FY ’26, including $5.5 billion in the second half. A $4.1 billion write‑down mainly tied to Vifor and further noncash impairments on assets such as part of the Lengnau site contributed to a statutory net loss to shareholders of $2.6 billion for the year. ## Vifor faces structural headwinds and sharp FY ’27 drop Vifor revenue grew 3% to $2.4 billion in reported terms, but management underscored deepening structural issues across the portfolio. Injectafer is contending with U.S. generics, European iron products saw 16% price‑driven decline, and setbacks around Velphoro and TAVNEOS underpin expectations for roughly a 25% revenue fall in FY ’27, weighing on group performance. ## China‑driven albumin weakness pressures margins Albumin revenue fell 17% in FY ’26, largely due to cost‑containment measures and shrinking market value in China, a key market for the product. Although the rate of decline moderated to a 5% drop in the second half, persistent pricing and market‑value pressure continue to drag on CSL Behring’s margin profile. ## Seqirus segment hit by loss of avian flu sales Beyond flu market share gains, Seqirus’s overall performance was dented by the nonrecurrence of the prior year’s avian influenza business. Segment revenue declined 8% and operating result fell 12%, as stronger seasonal products could not fully offset the absence of those one‑off sales, leaving year‑on‑year comparatives under pressure. ## Underlying profitability underwhelms despite revenue resilience Group revenue was broadly resilient at $15.8 billion, down 1% in constant currency, but profit metrics softened as mix and pricing pressures bit. NPATA before restructuring and impairments slipped 2% to $3.1 billion and underlying NPAT fell 3% to $2.8 billion, while Behring’s gross margin narrowed by about 70 basis points amid albumin weakness and U.S. channel normalization. ## Restructuring charges reshape the cost base CSL booked $799 million of restructuring charges in FY ’26, of which $339 million represented cash outflows, as it realigned operations and footprint. Significant noncash write‑downs on property, plant, and equipment, including part of the Lengnau site, also weighed on reported results but are intended to streamline the asset base for future returns. ## Guidance signals gradual recovery and ongoing capital returns Looking ahead, management expects transformation savings of around $220 million in FY ’27, taking annualized benefits to roughly $400 million and up to $550 million in FY ’28, with about half reinvested. Planned capex of about $1.0 billion, a fresh AUD 1.1 billion buyback, a maintained U.S. dollar dividend, and a targeted 1.5–2x net‑debt/EBITDA range underscore confidence in balance‑sheet strength. CSL’s earnings call outlined a company in transition, with strong cash generation, cost savings, and promising product launches laying the groundwork for a return to underlying profit growth. Yet the magnitude of Vifor’s headwinds, ongoing albumin and margin pressure, and the shadow of large impairments mean investors should brace for a choppy near term as the turnaround takes hold. ### Related Stocks - [CSLLY.US](https://longbridge.com/en/quote/CSLLY.US.md) - [CSL.AU](https://longbridge.com/en/quote/CSL.AU.md) - [HAE.US](https://longbridge.com/en/quote/HAE.US.md) ## Related News & Research - [CSL Director Exercises Rights to Acquire Additional Shares](https://longbridge.com/en/news/297138232.md) - [CSL (CMXHF) Announces Q4 Dividend: Read On for Important Dates](https://longbridge.com/en/news/296332317.md) - [MedicalRite Announces COVID-19 & Flu Combo Test for Better Health](https://longbridge.com/en/news/297204162.md) - [BNY Mellon Strategic Municipals declares $0.03 dividend](https://longbridge.com/en/news/297366155.md) - [Science Applications declares $0.37 dividend](https://longbridge.com/en/news/297327285.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**